Denali Therapeutics has been granted a patent for antibodies that specifically bind to the human BACE1 protein. The antibodies have modifications to enhance stability and reduce effector function. The patent also covers bispecific antibodies and pharmaceutical compositions for inhibiting amyloid-ß formation and treating neurodegenerative diseases. The claim specifies the amino acid sequences of the complementarity determining regions (CDRs) of the antibody. GlobalData’s report on Denali Therapeutics gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
According to GlobalData’s company profile on Denali Therapeutics, Cancer treatment biomarkers was a key innovation area identified from patents. Denali Therapeutics's grant share as of September 2023 was 16%. Grant share is based on the ratio of number of grants to total number of patents.
Antibodies that specifically bind to human bace1 protein
A recently granted patent (Publication Number: US11773185B2) discloses an isolated antibody or antigen-binding portion that specifically binds to a human beta-secretase 1 (BACE1) protein. The antibody or antigen-binding portion contains specific complementarity determining regions (CDRs) in its heavy and light chains. The CDRs in the heavy chain include CDR-H1, CDR-H2, and CDR-H3, while the CDRs in the light chain include CDR-L1, CDR-L2, and CDR-L3. The patent further describes various amino acid sequences for these CDRs, which can be used to generate the isolated antibody.
The patent also claims different combinations of CDR sequences for the isolated antibody, including specific combinations for the heavy chain and light chain. Additionally, the patent discloses that the isolated antibody can have a heavy chain variable region or a light chain variable region with at least 90% sequence identity to specific amino acid sequences. This indicates that the isolated antibody can have high similarity to these sequences.
Furthermore, the patent describes specific combinations of CDR sequences for the heavy chain and light chain that can be present in the isolated antibody. These combinations include different amino acid sequences for the heavy chain variable region and the light chain variable region.
The isolated antibody described in the patent can specifically bind to the human BACE1 protein with a binding affinity of less than about 75 nM. It can be a monoclonal antibody, a chimeric antibody, or a humanized antibody.
The patent also covers a pharmaceutical composition comprising the isolated antibody and a pharmaceutically acceptable carrier. Additionally, it discloses an isolated polynucleotide containing a nucleotide sequence encoding the isolated antibody or the humanized antibody.
In summary, the granted patent describes an isolated antibody or antigen-binding portion that specifically binds to the human BACE1 protein. It provides detailed information about the specific amino acid sequences for the complementarity determining regions in the heavy and light chains of the antibody. The patent also covers different combinations of these sequences and their use in pharmaceutical compositions.
To know more about GlobalData’s detailed insights on Denali Therapeutics, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies
